What are the second-line and subsequent treatment regimens for diffuse large B-cell lymphoma (DLBCL) in patients who are not candidates for high-dose therapy?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Second-line and subsequent therapy regimens, for patients who are not candidates for high-dose therapy, include the following:

  • Bendamustine ± rituximab
  • Brentuximab vedotin for CD30+ disease (category 2B)
  • CEPP (cyclophosphamide, etoposide, prednisone, procarbazine) ± rituximab - PO and IV
  • CEOP (cyclophosphamide, etoposide, vincristine, prednisone) ± rituximab
  • DA-EPOCH ± rituximab
  • GDP ± rituximab or (gemcitabine, dexamethasone, carboplatin) ± rituximab
  • GemOx ± rituximab
  • Gemcitabine, vinorelbine ± rituximab (category 3)
  • Lenalidomide ± rituximab (non-GCB DLBCL)
  • Rituximab

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!